Moderna Inc. (MRNA)
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.
Moderna: Q3 Earnings Preview - I Fear A Halloween Horror Show (Downgrade)
Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. Moderna's cost-cutting measures and cash reserves provide a buffer, but lack of new product launches and market competition challenge near-term growth. Oncology pipeline, especially mRNA-4157 and mRNA-4359, offers long-term promise, but regulatory and reimbursement hurdles remain substantial.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Moderna (MRNA) stood at $27.92, denoting a +2.12% move from the preceding trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
Moderna (MRNA) Declines More Than Market: Some Information for Investors
Moderna (MRNA) reached $23.51 at the closing of the latest trading day, reflecting a -7.4% change compared to its last close.
Is it Time to Dump Your Shares of Moderna?
Although you may not exactly understand what Moderna (MRNA 3.54%) does, you probably know the company's name, given its involvement in the coronavirus pandemic. The messenger RNA technology, or mRNA, the company uses to produce medicines is exciting, and it helped fast-track a working vaccine to fight back against COVID-19.
Moderna's stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop funding mRNA drug development.
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
